Dalutrafusp alfa is under clinical development by Agenus and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase II drugs for Pancreatic Ductal Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Dalutrafusp alfa LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dalutrafusp alfa overview
Dalutrafusp alfa (AGEN-1423) is under development for the treatment of metastatic pancreatic ductal adenocarcinoma, metastatic colorectal adenocarcinoma with liver metastases. It is based on retrocyte display technology and secant yeast display technology. It is administered through intravenous route. The therapeutic candidate is a bi-specific monoclonal antibody act by targeting immune checkpoint like CD73 and TGF-B.
It was under development for the treatment of advanced solid tumors including gastric or gastroesophageal junction adenocarcinoma and pancreatic cancer.
Agenus overview
Agenus is a biotechnology company. It is advancing therapies targeting cancer through a pipeline of immunological agents. The company’s portfolio includes several advanced platforms and programs designed to drive innovation in immuno-oncology (I-O). These consist of multiple proprietary antibody discovery platforms; antibody candidate programs such as botensilimab and balstilimab; a saponin-based vaccine adjuvant platform centered around the STIMULON cultured plant cell (CPC) QS-21 adjuvant and a pipeline of novel allogeneic invariant natural killer T (iNKT) cell therapies for treating cancer and other immune-mediated diseases. Agenus is headquartered in Lexington, Massachusetts, the US.
For a complete picture of Dalutrafusp alfa’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.